Skip to main content
Health & Medicine

Faecal microbiota transplantation in irritable bowel syndrome (REFIT2): a randomised, double-blind, placebo-controlled, phase 3 trial.

| Source: Lancet (London, England)

Gut microbiota composition might have a role in the pathogenesis of irritable bowel syndrome (IBS), and faecal microbiota transplantation has been proposed as a means of restoring healthy gut microbiota for individuals with this condition. We aimed to investigate the efficacy and safety of faecal microbiota transplantation in patients with IBS. In this parallel-group, randomised, double-blind, placebo-controlled, phase 3 trial, conducted at five hospitals in Norway, we enrolled men and women age

Gut microbiota composition might have a role in the pathogenesis of irritable bowel syndrome (IBS), and faecal microbiota transplantation has been proposed as a means of restoring healthy gut microbiota for individuals with this condition. We aimed to investigate the efficacy and safety of faecal microbiota transplantation in patients with IBS. In this parallel-group, randomised, double-blind, placebo-controlled, phase 3 trial, conducted at five hospitals in Norway, we enrolled men and women aged 18-65 years with moderate-to-severe IBS. IBS diagnosis was defined by the Rome IV criteria and an IBS-Severity Scoring System (IBS-SSS) score of 175 points or higher. A colonoscopy within 5 years before study enrolment was required for all participants aged 50 years or older to rule out colorectal cancer, and participants with IBS with predominantly diarrhoea required negative biopsies to exclude microscopic colitis. Participants were randomly assigned 2:1 to faecal microbiota transplantation with faeces samples from either healthy donors (intervention) or the participants themselves (placebo group). All investigators, participants, and study personnel involved in treatment administration, patient care, and outcome assessment were masked to treatment allocation throughout the study. Treatments were delivered as a once-only rectal enema. The primary endpoint was the proportion of participants with a reduction of 75 points or more in IBS-SSS score at 90 days after treatment compared with baseline, assessed in all patients who received their allocated treatment. All participants were advised to report any adverse event during follow-up to their study contact, preferably by telephone. A patient representative was involved in the planning of the trial. The trial was registered at ClinicalTrials.gov (NCT04691544). Between May 5, 2021, and July 14, 2022, we assessed 2304 individuals for eligibility, and 450 participants were enrolled and randomly assigned to the intervention group (299) or placebo group (151); two randomly assigned participants were excluded from analyses because their allocated treatments were switched. 293 (65%) of 448 participants were women, 155 (35%) were men, and the median age was 36 years (IQR 29-44). 119 (40%) participants in the donor faecal microbiota transplantation group and 57 (38%) in the placebo group showed an improvement of at least 75 points on the IBS-SSS at 90 days after treatment. The absolute difference was 1·9 percentage points (95% CI -8·1 to 12·0; p=0·76). The proportion of participants with adverse events was similar in the two study groups. The trial did not show a clinical benefit of faecal microbiota transplantation in patients with IBS. These findings suggest that microbiota modulation alone might be insufficient for symptom improvement in IBS. KLINBEFORSK.

Read the original source →

Related Topics

Related Stories

Health & Medicine

Homeostatic control of stem cell activity during intestinal regeneration.

Stem cells proliferate rapidly to maintain tissue turnover during regeneration, yet the mechanisms preventing hyperproliferation remain unclear. Here, we identified nuclear factor Y (NF-Y) as a transcriptional repressor that maintains intestinal stem cell (ISC) quiescence. NF-Y restricts ISC proliferation by occupying the promoters of epidermal growth factor receptor (EGFR) signaling components, including Egfr , Mkp3 , Raf , Ras , and pnt , through regulation dependent on the histone acetyltrans

Continue reading
Health & Medicine

Spatial transcriptomics reveals organizational properties of the mouse spinal cord and alterations in neuropathic pain.

The spinal cord integrates diverse somatosensory inputs and executes motor outputs through anatomically and functionally distinct circuits. Here, we employed spatially resolved single-cell transcriptomic profiling of the adult mouse spinal cord to gain insights into the organizational logic of the spinal cord. Our results reveal distinct spatial and laminar distributions of neuronal subtypes, including axial level and sex-specific differences. Many neuronal subtypes exhibit lamina-specific somat

Continue reading
Health & Medicine

Acute degradation of Pumilio proteins reveals a biphasic posttranscriptional regulatory hierarchy in embryonic stem cell fate decision.

Posttranscriptional regulation is critical for mammalian embryogenesis yet has been underexplored. We previously showed that RNA-binding Pumilio proteins (Pum1/2) are essential for early mouse embryogenesis and embryonic stem cell (ESC) functions. Here, using acute protein degradation systems combined with time-resolved RNA sequencing and enhanced crosslinking and immunoprecipitation, we delineate a two-phase regulatory hierarchy modulated by Pum1/2 in mouse ESCs. The first phase, occurring with

Continue reading
Health & Medicine

Elastic interactions of mechanically polarizable cells.

Cells mechanically interact through the deformations they generate in their surrounding extracellular matrix. We present an analytical theory of the elastic interactions between cells that actively adapt their forces in response to local deformations of their environment. Cells are represented as localized contractile force generators, modeled as polarizable point force dipoles, whose adaptive forces are determined self-consistently with those of surrounding cells. Analysis of the associated ela

Continue reading
Health & Medicine

ChREBP drives diabetic kidney disease, and its inhibition confers renal protection.

Chronic kidney disease (CKD) represents a major medical burden. Diabetic kidney disease (DKD) is a leading cause of CKD, but intracellular pathways that can be pharmacologically targeted are poorly defined. Using transcriptome screening of DKD model mice we found that a carbohydrate-responsive element-binding protein (ChREBP)-dependent transcriptional cascade is markedly up-regulated in diabetic kidneys. Genetic ablation of ChREBP in diabetic mice ameliorated DKD, establishing ChREBP as a potent

Continue reading